Nexalin Technology (NXL) Net Cash Flow Growth (3y) (2024 - 2026)
Nexalin Technology (NXL) Net Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 269.22% |
| 10 | Nexalin Technology | 7.04 Mn | 6.03 Mn | 8,897.00 | -77.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -77.32% |
| Mar 31, 2026 | 256.40% |
| Dec 31, 2025 | 27.47% |
| Sep 30, 2025 | -72.43% |
| Jun 30, 2025 | -206.94% |
| Mar 31, 2025 | 30.73% |
| Dec 31, 2024 | -2.09% |